Skip to main content

Table 1 Characteristics of individuals exposed and not exposed to ETR + PI contributing to follow-up, measured in number of persons-years

From: Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens

All patients (person-years) All patients No ETR + PI ETR + PI p
13,985.68 11,666.71 2318.96
Age at baseline
 18–29 years 333.96 (2.4%) 286.02 (2.5%) 47.94 (2.1%) < 0.0001
 30–39 years 3050.51 (21.8%) 2699.57 (23.1%) 350.94 (15.1%)  
 40–59 years 9754.3 (69.7%) 7973.02 (68.3%) 1781.28 (76.8%)
 >=60 years 846.91 (6.1%) 708.10 (6.1%) 138.81 (6.0%)
Gender and transmission group
 Men who have sex with men 5462.59 (39.1%) 4392.05 (37.6%) 1070.41 (46.2%) < 0.0001
 Injecting drug users 2393.23 (17.1%) 2087.84 (17.9%) 305.39 (13.2%)  
 Other men 2788.01 (19.9%) 2258.16 (19.4%) 529.94 (22.8%)
 Other women 3341.84 (23.9%) 2928.67 (25.1%) 413.17 (17.8%)
Geographic origin
 Sub-Saharan Africa 1218.56 (8.7%) 970.62 (8.3%) 247.94 (10.7%) 0.0002
 Other 12,767.12 (91.3%) 10,696.10 (91.7%) 2071.02 (89.3%)  
HCV co-infection status
 No 11,650.70 (83.3%) 9643.24 (82.7%) 2007.47 (86.6%) < 0.0001
 Yes 2334.96 (16.7%) 2023.47 (17.3%) 311.49 (13.4%)  
Centre - Total follow-up of heavily treated individuals
 < 140 P-Y 2575.17 (18.4%) 2118.09 (18.2%) 457.02 (19.7%) < 0.0001
 140–240 P-Y 3254.79 (23.3%) 2717.26 (23.3%) 537.53 (23.2%)  
 240–400 P-Y 3895.42 (27.9%) 3354.69 (28.8%) 540.73 (23.3%)
 ≥ 400 P-Y 4260.31 (30.5%) 3476.68 (29.8%) 783.63 (33.8%)
Calendar period
 2005–2006 8760.93 (62.6%) 8517.74 (73.0%) 243.19 (10.5%) < 0.0001
 2007–2008 3779.28 (27.0%) 2280.19 (19.5%) 1499.09 (64.6%)  
 2009–2011 1445.46 (10.3%) 868.78 (7.4%) 576.68 (24.9%)
Nadir CD4 count (cells/mm3) at baseline
 < 50 5090.31 (36.4%) 3973.69 (34.1%) 1116.62 (48.2%) < 0.0001
 50–100 2395.85 (17.1%) 1989.13 (17.0%) 406.72 (17.5%)  
 100–200 3564.30 (25.5%) 3075.84 (26.4%) 488.46 (21.1%)
 ≥ 200 2935.22 (21.0%) 2628.05 (22.5%) 307.16 (13.2%)
CD4 count (cells/mm3) at baseline
 < 200 4879.74 (34.9%) 3871.50 (33.2%) 1008.24 (43.5%) < 0.0001
 200–350 4083.24 (29.2%) 3521.03 (30.2%) 562.21 (24.2%)  
 350–500 2537.01 (18.1%) 2173.42 (18.6%) 363.59 (15.7%)
 ≥ 500 2485.68 (17.8%) 2100.76(18.0%) 384.92 (16.6%)
VL (copies/mL) at baseline
 50–500 2824.38 (20.2%) 2301.04 (19.7%) 523.34 (22.6%) < 0.0001
 500–5000 3255.58 (23.3%) 2763.23 (23.7%) 492.35 (21.2%)  
 5000–30,000 2930.25 (21.0%) 2408.75 (20.6%) 521.50 (22.5%)
 30,000–100,000 2501.51 (17.9%) 2059.86 (17.7%) 441.65 (19.0%)
 > 100,000 2473.97 (17.7%) 2133.85 (18.3%) 340.12 (14.7%)
Previous AIDS defining events at baseline
 No 8274.24 (59.2%) 7116.34 (61.0%) 1157.90 (49.9%) < 0.0001
 Yes 5711.44 (40.8%) 4550.31 (39.0%) 1161.06 (50.1%)  
Prophylaxis (Cotrimoxazole, Dapsone, Pentamidine)
 Not eligible (CD4 > 200) 8093.10 (57.9%) 6969.47 (59.7%) 1123.63 (48.5%) < 0.0001
 No 1821.36 (13.0%) 1378.35 (11.8%) 443.01 (19.1%)  
 Yes 4071.22 (29.1%) 3318.89 (28.5%) 752.33 (32.4%)
Number of prior ARVs
 5–8 3749.64 (26.8%) 3609.96 (30.9%) 139.69 (6.0%) < 0.0001
 9–10 3816.28 (27.3%) 3520.84 (30.2%) 295.44 (12.7%)  
 11–13 4084.10 (29.2%) 3281.11 (28.1%) 802.99 (34.6%)
 > 13 2335.66 (16.7%) 1254.81 (10.8%) 1080.85 (46.6%)